You are here: Industry Insights > Innoviva

News List

GSK to sell stake in Innoviva for $392m pharmaceutical-technology
May 24, 2021
GlaxoSmithKline (GSK) has entered a definitive agreement to sell its entire equity stake in royalty management company Innoviva at $12.25 for each share, taking the deal proceeds to a total of nearly $392m.
EU expands label of GSK/Innoviva’s COPD inhaler pharmatimes
November 14, 2018
GSK noted that while bronchodilation is recognised as the foundation of COPD therapy, “many patients may continue to struggle with symptoms and exacerbations over time”.
Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences pharmaceutical-technology
August 07, 2017
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.
Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences pharmaceutical-technology
August 04, 2017
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.